Experience to work on bb2121 Cell Therapy program: author and review documents; review data.
Answer: Yes, knowing the priciple and date dacument processes.
Respond to regulatory questions on filings.
Answer: Yes, to a particular issue or questionaires.
Can also be placed in Seattle, Boudry or other sites.
Answer: Yes, location and relo- should not be a problem.
Supports data management as required for CRF development, database edit checks development, listings review, query resolution, database clean-up and lock activities.
Answer: Yes, as neccesary and required.
Prepares clinical study timelines and status reports.
Answer: Yes.
Chimeric antigen receptor (CAR) T-cell therapy has emerged as a novel treatment that has the potential for long-term disease control in some hematologic cancers,10-12 with anti-CD19 CAR T-cell therapies showing efficacy in patients with leukemia or lymphoma.13-22 B-cell maturation antigen (BCMA) is a member of the tumor necrosis factor superfamily of proteins that is primarily expressed by malignant and normal plasma cells and some mature B cells, making it a potential target for multiple myeloma.
